Elicio Therapeutics appoints Preetam Shah as Chief Strategy and Financial Officer

Elicio Therapeutics, Inc.

Preetam Shah appointed Chief Strategy and Financial Officer effective March 24, 2025; will become Principal Financial Officer and Principal Accounting Officer on April 1, 2025.
Annual base salary $480,000; target bonus of 40% of base; initial option grant equal to 1.2% of outstanding shares as of April 15, 2025, vesting over 4 years.
Shah previously served as CFO/CBO at Cidara Therapeutics (Sept 2021–Feb 2025) and CFO & Treasurer at Brainstorm Cell Therapeutics (Sept 2019–Aug 2021).
The company highlights upcoming Phase 2 AMPLIFY-7P disease-free survival interim analysis for cancer immunotherapy ELI-002.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Preetam Shah

Chief Strategy and Financial Officer

ELTX · Elicio Therapeutics, Inc.

Effective: 2025-03-24
Filed: March 24, 2025, 7:59 PM ET

On March 21, 2025, Elicio Therapeutics, Inc. (the “Company”) appointed Preetam Shah, Ph.D., M.B.A., as the Company’s Chief Strategy and Financial Officer effective as of March 24, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Preetam Shah was appointed as Chief Strategy and Financial Officer at Elicio Therapeutics, Inc..

Action: appointed
Role: Chief Strategy and Financial Officer

Exact text from the filing

On March 21, 2025, Elicio Therapeutics, Inc. (the “Company”) appointed Preetam Shah, Ph.D., M.B.A., as the Company’s Chief Strategy and Financial Officer effective as of March 24, 2025 (the “Effective Date”).

View on SEC.gov

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-25-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.